WA
BPMC

Waverly Advisors’s Blueprint Medicines BPMC Stock Holding History

Waverly Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,957
Closed -$4.35M – 1286
2025
Q2 		$4.35M Sell
33,957
-721
-2% -$74.9K 0.05% 327
2025
Q1 		$3.07M Buy
+34,678
New +$3.38M 0.04% 389

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Waverly Advisors's BPMC Position: Q3 2025 in Review

Waverly Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 33,957 shares — an estimated $4.35M sold.

Waverly Advisors first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $4.35M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Waverly Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Waverly Advisors sold 33,957 Blueprint Medicines shares in Q3 2025, an estimated $4.35M.
  • Waverly Advisors first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
  • Waverly Advisors's Blueprint Medicines position peaked at $4.35M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Waverly Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.